Thio-TEPACAS# 52-24-4 |
- Lenalidomide hydrochloride
Catalog No.:BCC1697
CAS No.:1243329-97-6
- Celastrol
Catalog No.:BCN5986
CAS No.:34157-83-0
- Necrostatin 2 racemate
Catalog No.:BCC2077
CAS No.:852391-15-2
- Necrostatin 2
Catalog No.:BCC1793
CAS No.:852391-19-6
- Necrostatin 2 S enantiomer
Catalog No.:BCC2078
CAS No.:852391-20-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 52-24-4 | SDF | Download SDF |
| PubChem ID | 5453 | Appearance | Powder |
| Formula | C6H12N3PS | M.Wt | 189.22 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (264.24 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | tris(aziridin-1-yl)-sulfanylidene-$l^{5}-phosphane | ||
| SMILES | C1CN1P(=S)(N2CC2)N3CC3 | ||
| Standard InChIKey | FOCVUCIESVLUNU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Thio-TEPA Dilution Calculator
Thio-TEPA Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.2849 mL | 26.4243 mL | 52.8485 mL | 105.6971 mL | 132.1213 mL |
| 5 mM | 1.057 mL | 5.2849 mL | 10.5697 mL | 21.1394 mL | 26.4243 mL |
| 10 mM | 0.5285 mL | 2.6424 mL | 5.2849 mL | 10.5697 mL | 13.2121 mL |
| 50 mM | 0.1057 mL | 0.5285 mL | 1.057 mL | 2.1139 mL | 2.6424 mL |
| 100 mM | 0.0528 mL | 0.2642 mL | 0.5285 mL | 1.057 mL | 1.3212 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Thio-TEPA is a DNA alkylating agent, with antitumor activity.
In Vitro:Thio-TEPA exhibits alkylating activity in rat liver slice incubation. Thio-TEPA does not affect the viability of rat liver slices, and is not accumulated in the slices at all doses of 2, 5, 10 mM[1].
In Vivo:Thio-TEPA (20 mg/kg, i.p.) with total body irradiation (TBI) enhances donor-type blood chimerism during the first 10 weeks but is not dramatically higher than that of TBI group alone. Thio-TEPA alone improves both short- and long-term engraftment in mice[2].
References:
[1]. Hagen B, et al. Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation. Cancer Chemother Pharmacol. 1991;28(6):441-7.
[2]. Down JD, et al. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Bone Marrow Transplant. 1998 Feb;21(4):327-30.
- Prednisolone Acetate
Catalog No.:BCC4831
CAS No.:52-21-1
- Spironolactone
Catalog No.:BCC4366
CAS No.:52-01-7
- Dehydroespeletone
Catalog No.:BCN5652
CAS No.:51995-99-4
- Schaftoside
Catalog No.:BCN2343
CAS No.:51938-32-0
- 5-Aminoindole
Catalog No.:BCC8735
CAS No.:5192-03-0
- TNP
Catalog No.:BCC7822
CAS No.:519178-28-0
- CJ 033466
Catalog No.:BCC7562
CAS No.:519148-48-2
- Tasisulam
Catalog No.:BCC4407
CAS No.:519055-62-0
- Dehydrohautriwaic acid
Catalog No.:BCN7586
CAS No.:51905-84-1
- 4-(N-Methyl)-aminoantipyrine
Catalog No.:BCC8652
CAS No.:519-98-2
- Sulochrin
Catalog No.:BCN6959
CAS No.:519-57-3
- Maclurin
Catalog No.:BCN5651
CAS No.:519-34-6
- Morphine hydrochloride
Catalog No.:BCC6368
CAS No.:52-26-6
- H-D-Pen-OH
Catalog No.:BCC3307
CAS No.:52-67-5
- Lynestrenol
Catalog No.:BCC9014
CAS No.:52-76-6
- Haloperidol
Catalog No.:BCC4909
CAS No.:52-86-8
- H-Cys-OH
Catalog No.:BCC2902
CAS No.:52-90-4
- 6-Methoxyluteolin
Catalog No.:BCN3613
CAS No.:520-11-6
- Pectolinarigenin
Catalog No.:BCN5813
CAS No.:520-12-7
- Kaempferol
Catalog No.:BCN5653
CAS No.:520-18-3
- Hesperidin
Catalog No.:BCN5654
CAS No.:520-26-3
- Diosimin
Catalog No.:BCN4993
CAS No.:520-27-4
- Tectochrysin
Catalog No.:BCN5655
CAS No.:520-28-5
- Tricin
Catalog No.:BCN5656
CAS No.:520-32-1
A pharmacokinetic and clinical evaluation of thio-TEPA in combination with cisplatin as first-line chemotherapy for advanced epithelial ovarian carcinoma.[Pubmed:11240751]
Int J Gynecol Cancer. 1999 Mar;9(2):110-116.
The purpose of the study was to explore the combination of Thio-TEPA with cisplatin in first-line chemotherapy of epithelial ovarian cancer with special reference to pharmacokinetic and pharmacodynamic relationships. Ten women with advanced disease were included. Pharmacokinetics of Thio-TEPA were similar to those in previous studies of single drug therapy with rapid first order elimination of the parent drug and substantial intra- and interindividual variation of the area under the concentration-time curve (AUC). No effects of the drug sequence or repeated treatments were seen on the pharmacokinetics of Thio-TEPA, indicating no significant influence from the coadministration of cisplatin on the distribution, metabolism or excretion of Thio-TEPA. Pharmacokinetic--pharmacodynamic relationships were less pronounced compared to previous studies, probably due to the influence from cisplatin. Prolongation of treatment intervals, dosage reduction, and withholding of Thio-TEPA were required due to myelosuppression, which was the dominating toxicity. Non-hematological toxicity was moderate and easily manageable, cisplatin-related toxicity did not seem to be aggravated. Response rate based on CA 125 fluctuations was 80%, overall median survival was 18 months. In conclusion, the pharmacokinetics of Thio-TEPA does not seem to be significantly influenced by concomitant administration of cisplatin in female patients. Manageable toxicity, largely restricted to myelosuppression, and high response rate justify further evaluation of the current regimen.
Gender aspects of liver slice incubations with N,N,N-triethylene-thiophosphamide (Thio-TEPA) in rats and mice.[Pubmed:10193672]
Pharmacol Toxicol. 1999 Mar;84(3):122-4.
This study was conducted to investigate if biotransformation of N,N,N-triethylene-thiophosphoramide (Thio-TEPA) by liver slice incubations reflects the established gender pattern for rat and mouse. Liver slices from rat and mice of both genders were incubated with start concentrations of Thio-TEPA of 5.2, 26, 52 and 104 microM for up to 240 min. Male rat liver slices eliminated Thio-TEPA faster and formed more TEPA than female liver slices at any concentration. No gender difference was found for the elimination of Thio-TEPA in mice, however, the female liver slices formed less TEPA than the male ones. Apparently female rat liver slices formed less TEPA than female mice liver slices. It is concluded that the liver slice incubation system in a robust manner reflects gender differences in rat drug biotransformation with special reference to Thio-TEPA. It is also confirmed that these aspects of gender are less pronounced in the examined mouse species than in rats.
Sensitivity of p53-deficient cells to oxaliplatin and thio-TEPA (N, N', N" triethylenethiophosphoramide).[Pubmed:12058967]
Breast Cancer Res Treat. 2002 Apr;72(3):255-63.
P53 is known as a determinant of cellular responses to DNA damage, including apoptosis, cell cycle arrest, and DNA repair. Its role is most easily understood in the context of Burkitt lymphoma and other apoptosis-prone cell types. A number of epithelial cancer cell types, by contrast, exhibit a higher threshold for apoptosis induction in response to DNA damage. In fact, p53 mediates DNA repair and protective responses in the latter cell types, in some cases p53-deficient cells being more sensitive to DNA damage, antithetical to the situation in Burkitt lymphoma and other apoptosis-prone cell types. Ultraviolet light, cisplatin, and nitrogen mustards produce damage that is repaired by a p53-regulated pathway. Here, we explore the sensitivity of the platinum compound oxaliplatin and Thio-TEPA (N, N', N", triethylenethiophosphoramide), a cancer chemotherapeutic agent that produces largely base damage, in p53-defective cells. This work demonstrates that the contribution of p53 temporally correlates with DNA repair pathways to produce a resistant phenotype, while the p53-defective cells are more sensitive to certain DNA-damaging chemotherapeutic agents.
[A comparative study of thio-tepa and mitomycin C in the treatment of pterygium. Preliminary results].[Pubmed:9759389]
J Fr Ophtalmol. 1998 Feb;21(2):96-102.
AIMS: To compare the efficacy of Thio-TEPA and Mitomycine C to obviate recurrence; to compare cost-efficacy ratios; to evaluate their facility of use and their complications. METHODS: In a prospective blinded study, 36 patients undergoing surgery for 46 primary and recurrent pterygium were assigned randomly to three groups: group 1 received 0.02 mg/ml of Mitomycine C three times daily for 5 days; group 2 received Thio-TEPA four times daily for 6 weeks, group 3 served as a control receiving distilled water three times daily for five days. RESULTS: Recurrence rates were 38%, in group 1; 28% in group 2; 82% in group 3 respectively. Follow-up ranged from 15 to 44 weeks (mean 27.93 +/- 8.9 weeks). Mean delay recurrence time was 6.3 weeks. Topical Mitomycin caused: iritis, conjunctival irritation, excessive lacrymation, photophobia, ocular pain; Thio-TEPA caused: photophobia, foreign body sensation, headache. CONCLUSIONS: Mitomycine C appears to be an effective and safe adjunctive treatment for this cost-efficacy and this facility of use comparison.
